No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antineoplastic Agents / adverse effects*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Cryptogenic Organizing Pneumonia / chemically induced*
-
Cryptogenic Organizing Pneumonia / diagnosis
-
Diagnosis, Differential
-
Disease Progression*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Nivolumab
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Nivolumab